Dr. Nicholette L. Erickson

Hematology Oncology | Hematology | Oncology
1701 Thomson Dr, 
Lynchburg, VA 
1701 Thomson Dr, 
Lynchburg, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nicholette Erickson is a Hematologist Oncology specialist and a Hematologist in Lynchburg, Virginia. Dr. Erickson is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Her clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Bridgton Hospital
Centra Health - Lynchburg Gen Hospital
Central Maine Medical Center
Rumford Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CENTRA MEDICAL GROUP LLC
1701 Thomson Dr, Lynchburg, VA 24501
Other Locations
CENTRA MEDICAL GROUP LLC
1901 Tate Springs Rd, Lynchburg, VA 24501
CENTRAL MAINE MEDICAL CENTER
300 Main St, Lewiston, ME 04240

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Other, Procedure
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials
Similar Doctors
Advanced in Prothrombin Deficiency
Dr. Andrew E. Fintel
Hematology Oncology | Hematology | Oncology
Advanced in Prothrombin Deficiency
Dr. Andrew E. Fintel
Hematology Oncology | Hematology | Oncology

Oncology And Hematology Associates Of Southwest Virginia Inc

1900 Electric Rd, Blue Ridge Cancer Care, 
Salwm, VA 
 (48.4 miles away)
540-774-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Fintel is a Hematologist Oncology specialist and a Hematologist in Salwm, Virginia. Dr. Fintel is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Paget Disease of the Breast, Colorectal Cancer, Familial Colorectal Cancer, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Fintel is currently accepting new patients.

Experienced in Prothrombin Deficiency
Dr. Kimberly L. Aderhold
Hematology Oncology | Hematology | Oncology
Experienced in Prothrombin Deficiency
Dr. Kimberly L. Aderhold
Hematology Oncology | Hematology | Oncology

Oncology And Hematology Associates Of Southwest Virginia Inc

1900 Electric Rd, Blue Ridge Cancer Care, 
Salwm, VA 
 (48.4 miles away)
540-774-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kimberly Aderhold is a Hematologist Oncology specialist and a Hematologist in Salwm, Virginia. Dr. Aderhold is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Folate-Deficiency Anemia, and Hemochromatosis. Dr. Aderhold is currently accepting new patients.

Experienced in Prothrombin Deficiency
Dr. Donald C. Vile
Hematology Oncology | Geriatrics | Hospital Medicine
Experienced in Prothrombin Deficiency
Dr. Donald C. Vile
Hematology Oncology | Geriatrics | Hospital Medicine

Oncology And Hematology Associates Of Southwest Virginia Inc

2013 Jefferson St Sw, 
Roanoke, VA 
 (43.9 miles away)
540-982-0237
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Donald Vile is a Hematologist Oncology specialist and a Geriatrics provider in Roanoke, Virginia. Dr. Vile is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Childhood Iron Deficiency Anemia, Lung Cancer, and Iron Deficiency Anemia. Dr. Vile is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Erickson's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 112 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile